Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple Turns 50: From Garage Startup to AI Crossroads 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
GAITHERSBURG, Md., Sept. 05, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi’s 12th Annual Biotech Conference.
Conference details are as follows:
Date: Thursday, September 7, 2017
Location: Mandarin Oriental hotel, Boston, MA
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Maggie Beller [email protected] [email protected] 212-845-4271
